Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Walter M. Stadler

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Stadler, Walter

PropertyValue
keywords Prostate Cancer
overview Dr. Stadler is a clinical trialist focused on developing novel therapies and biomarkers, especially for genitourinary cancer. In addition to an extensive history performing trials in kidney, bladder, and prostate cancer, he also has broad experience in leading efforts supporting clinical trial infrastructure and conduct. These include renal cancer cadre leader for the Cancer and Leukemia Group B (CALGB, now Alliance), PI for a DOD funded prostate cancer clinical trials consortium, co-PI for a Prostate Cancer SPORE, PI for the NCI funded N01 contract for early phase clinical trials, and a current role as Dean for Clinical Research

One or more keywords matched the following items that are connected to Stadler, Walter

Item TypeName
Concept Prostatic Neoplasms
Academic Article Prostate cancer metastasis-suppressor genes: a current perspective.
Academic Article Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases.
Academic Article Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
Academic Article Docetaxel and exisulind in hormone-refractory prostate cancer.
Academic Article Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
Academic Article New trial designs to assess antitumor and antiproliferative agents in prostate cancer.
Academic Article Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Academic Article Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site.
Academic Article 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
Academic Article A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Academic Article Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
Academic Article Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis.
Academic Article A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Academic Article Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
Academic Article A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Academic Article Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Academic Article A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Academic Article The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
Academic Article Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
Academic Article Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.
Academic Article A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.
Academic Article A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Academic Article Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis.
Academic Article Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Academic Article Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging.
Academic Article A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
Academic Article Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
Academic Article A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
Academic Article FYN is overexpressed in human prostate cancer.
Academic Article Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.
Academic Article Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
Academic Article MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
Academic Article Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Academic Article Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
Academic Article Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.
Academic Article Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Academic Article Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.
Academic Article Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
Academic Article Dynamic contrast-enhanced MR imaging findings of bone metastasis in patients with prostate cancer.
Academic Article Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.
Academic Article Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
Academic Article Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
Academic Article A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer.
Academic Article Nilutamide: possible utility as a second-line hormonal agent.
Academic Article Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Academic Article Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Academic Article A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
Academic Article Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
Academic Article Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy.
Academic Article Novel approaches and future directions in castration-resistant prostate cancer.
Academic Article Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study.
Academic Article A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
Academic Article MR imaging-guided focal laser ablation for prostate cancer: phase I trial.
Academic Article Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.
Academic Article Low-grade prostate cancer diverges early from high grade and metastatic disease.
Academic Article Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Academic Article The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Academic Article Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Academic Article Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
Academic Article Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.
Academic Article Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Academic Article A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.
Academic Article Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
Academic Article Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Academic Article The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.
Academic Article Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
Academic Article Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial.
Academic Article Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Academic Article Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Academic Article Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.
Academic Article Low-Dose Abiraterone With Food: Rebutting an Editorial.
Academic Article Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Academic Article Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Academic Article EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.

Search Criteria
  • Prostate Cancer